Sera Prognostics(US:SERA) Prnewswire·2025-05-08 20:40Company Overview - Sera Prognostics is a leading health diagnostics company focused on improving the lives of women and babies through precision pregnancy care [3] - The company's mission is to provide early, pivotal pregnancy information to enhance maternal and newborn health, ultimately reducing healthcare delivery costs [3] - Sera has a robust pipeline of innovative diagnostic tests aimed at early prediction of preterm birth risk and other pregnancy complications [3] Leadership Appointment - Mr. Lee Anderson has been appointed to a leadership role at Sera Prognostics, bringing extensive experience in the biotechnology and diagnostics sector [1] - Anderson previously held significant positions at Genomic Health and Exact Sciences, where he led US Oncology Sales and Global Customer Service, achieving nine consecutive years of revenue growth [1][2] - His role at Biofidelity Inc. as Chief Commercial Officer further enhanced his commercial strategy expertise and market presence [2] PreTRM® Test - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify at-risk women between weeks 18 and 20 of pregnancy [5] - The PreTRM® Test enables more informed and personalized clinical decisions based on individual risk assessments [5] Preterm Birth Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last six years, more than one in ten infants in the United States has been born prematurely, leading to significant long-term medical complications [4] - The estimated annual healthcare costs for managing complications related to prematurity in the U.S. were approximately $25 billion in 2016 [4]